ClinicalTrials.gg
Not yet recruitingNCT07740720DuraSTARUpdated Nov 16, 2026

A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

A Phase 3 interventional study of Dostarlimab in Neoplasms, Rectal, sponsored by GlaxoSmithKline. Not yet recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026First site in JapanStart date moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 26 studies in Rectal Neoplasms with a site in Japan — 7 open to participants now, 12 under way, 5 of them phase 3. Rectal Neoplasms · Japan.

Planned enrollment
13th of 24
100 · median 105
Started
2026
the only one that year
Phase 3
8 of 26
4 open now
Primary completion
2030-03
later than 11 of 11 live
Registered
26th of 26
by date
Lead sponsor
4 of 26
GlaxoSmithKline

Among the 26 studies in Rectal Neoplasms with a site in Japan, this one is the 13th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 8 in phase 3, reaches primary completion later than 11 of the 11 other live ones, and was the 26th registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

7 of the 26 studies in Rectal Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 405 Rectal Neoplasms studies recruiting now, 210 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Rectal Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to treatment and avoid standard treatments like chemotherapy, radiation treatment, or surgery. Scans and endoscopy tests will be conducted to see if the tumor disappears and how long the cancer stays under control. The study will also collect information on side effects and health outcomes after dostarlimab.

03

Conditions studied

  • Neoplasms, Rectal

Browse trials for

Keywords

  • GSK4057190
  • Dostarlimab
  • dMMR
  • MSI-H
  • Locally advanced rectal cancer
  • DuraSTAR
  • PD-1
  • LARC
  • Anti-PD1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed Stage II to III (T3-T4, N0, or T any, N+) locally advanced rectal adenocarcinoma.
  • Has radiologically and endoscopically evaluable disease.
  • Has a tumor demonstrating the presence of either:

    1. dMMR status; MMR status must be assessed by immunohistochemistry for MMR protein expression (MLH1, MSH2, MSH6, PMS2) where loss of 1 or more proteins indicates dMMR; MMR status will be determined locally; or
    2. MSI-H phenotype as determined by polymerase chain reaction or by tissue next generation sequencing; MSI-H will be determined locally.
  • Has an (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has received prior radiation therapy, systemic therapy, or surgery for management of rectal cancer.
  • Has a tumor that, in the investigator's judgment, is causing symptomatic bowel obstruction or otherwise requires urgent/emergent local intervention. Participants with a history of bowel obstruction are eligible after obstruction is relieved by a diverting stoma (defunctioning colostomy). Patients with a history of bowel obstruction in the context of current rectal cancer diagnosis and treated with stenting are not eligible.
  • Has an active disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, , or drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.
  • Has undergone any major surgical procedure, open , or experienced significant traumatic injury within 28 days prior to enrollment.
  • Is receiving any other anticancer or experimental therapy.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Dostarlimab

    Biological: Dostarlimab

Interventions

  • BiologicalDostarlimab

    Dostarlimab will be administered.

    Also known as: GSK4057190, dostarlimab-gxly, TSR-042

06

What researchers measure

Primary outcomes

  1. Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment

    Time frame: Up to 168 weeks

Secondary outcomes

  1. Overall cCR rate by investigator assessment

    Overall cCR rate is defined as the percentage of participants achieving cCR by investigator assessment at any disease assessment, regardless of duration of dostarlimab therapy among all enrolled participants.

    Time frame: Up to 171 weeks

  2. Number of participants with sustained clinical complete response at 12 months (cCR12) as assessed by investigator

    cCR12 is defined as achievement and maintenance of cCR for 12 months from the disease assessment after the last dose of study intervention that first demonstrates cCR by investigator assessment.

    Time frame: Up to 171 weeks

  3. Objective response rate (ORR) as assessed by investigator

    ORR is defined as the percentage of participants who achieve a best clinical response of partial response (PR), near complete response (nCR), or clinical complete response (cCR) at any disease assessment.

    Time frame: Up to 171 weeks

  4. Number of participants with composite cCR12 and pathologic complete response (pCR) as assessed by investigator

    The composite endpoint of cCR12 and pCR is defined as the number of participants who either achieve cCR12, or achieve pCR after receiving dostarlimab (before receiving standard of care)

    Time frame: Up to 171 weeks

  5. Time to cCR

    Time to cCR is defined as the time from the first dose of study intervention to the time of first cCR as assessed by the investigator.

    Time frame: Up to 171 weeks

  6. Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse event (imAEs), and AEs leading to death or discontinuation of study intervention by severity

    Time frame: Up to 171 weeks

07

Study locations

1 site
  • GSK Investigational Site
    Fukuoka, 812-8582, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2030, 38 months later.

Of 81 phase 3 interventional studies under Rectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 95. This study's planned 38 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Sep 2026 → Dec 2026, primary completion Dec 2029 → Mar 2030 and completion Dec 2029 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Aug 3, 2026
StartEst.
Dec 17, 2026was Sep 2026
Primary completionEst.
Mar 13, 2030was Dec 2029
CompletionEst.
Apr 1, 2030was Dec 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Japan
Show site
  • GSK Investigational Site · Fukuoka, Japan
Nov 16, 2026
Start date
Sep 17, 2026→Dec 17, 2026
Nov 16, 2026
Primary completion
Dec 12, 2029→Mar 13, 2030
Nov 16, 2026
Study completion
Dec 31, 2029→Apr 1, 2030
Nov 16, 2026
Enrollment
90→100
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    1 site added — first site in Japan
    Show site
    • GSK Investigational Site · Fukuoka, Japan
    Start date Sep 17, 2026→Dec 17, 2026
    Primary completion Dec 12, 2029→Mar 13, 2030
    Study completion Dec 31, 2029→Apr 1, 2030
    Enrollment 90→100
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07740720
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 3, 2026
Start date
Dec 17, 2026 (estimated)
Primary completion
Mar 13, 2030 (estimated)
Completion
Apr 1, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dostarlimab

Start the discussion